- Home
- HGV vs AKRO Comparison
HGV vs AKRO Comparison
Compare HGV & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HGV | AKRO |
|---|---|---|
| Founded | 1992 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | HGV | AKRO |
|---|---|---|
| Price | $42.32 | $54.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $49.75 | ★ $73.56 |
| AVG Volume (30 Days) | 826.4K | ★ 1.7M |
| Earning Date | 10-30-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $4,470,000,000.00 | N/A |
| Revenue This Year | $14.74 | N/A |
| Revenue Next Year | $9.35 | N/A |
| P/E Ratio | $75.97 | ★ N/A |
| Revenue Growth | ★ 5.47 | N/A |
| 52 Week Low | $30.59 | $21.34 |
| 52 Week High | $52.08 | $58.40 |
Technical Indicators
Market Signals| Indicator | HGV | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 66.54 |
| Support Level | $41.42 | $54.22 |
| Resistance Level | $42.92 | $54.70 |
| Average True Range (ATR) | 1.19 | 0.14 |
| MACD | 0.47 | -0.11 |
| Stochastic Oscillator | 86.92 | 64.18 |
Price Performance
Historical ComparisonAbout HGV Hilton Grand Vacations Inc.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.